Newburyport (MA, USA) – ABL Diagnostics, a Euronext-listed company, has announced the opening of a new temperature-controlled warehouse in the USA for its affiliate, AdvancedDx Biological Laboratories USA Inc. The warehouse, located in New Jersey, will provide improved quality and speed of service to clients and partners.
This new warehouse is the result of a Logistics and Warehousing Agreement between AdvancedDx Biological Laboratories USA Inc. and VELA Diagnostics USA Inc. The warehouse specializes in warehousing and transportation of biomedical and general laboratory products, as well as medical devices for research laboratories and hospitals. This warehouse is compliant with Good Distribution Practices (GDP).
According to Ronan Boulme, ABL Diagnostics GRC Director, the opening of this warehouse is a significant step forward for AdvancedDx Biological Laboratories USA Inc. Boulme states, “This brand new warehouse consolidates our presence in the USA and underlines our constant commitment to providing clients and partners with an excellent service dedicated exclusively to the healthcare sector.”
Sam Dajani, Chairman & Chief Executive Officer at Vela Operations Singapore Pte. Ltd., also commented on the partnership, stating, “Through this Logistics and Warehousing Agreement, we initiate an important move with ABL Diagnostics, which has the potential to strengthen the relationship between both companies, globally.”
AdvancedDx Biological Laboratories USA Inc is an affiliate of ABL Diagnostics S.A., a leading international company that offers innovative molecular biology assays for genotyping through DNA sequencing – DeepChek®. ABL Diagnostics, based in Woippy, is a public company listed on Euronext’s regulated market in Paris (Euronext: ABLD – ISIN: FR001400AHX6). Their molecular biology products generate recurring revenues and cover one of the largest portfolios of microbiology applications.
ABL Diagnostics sells its products worldwide through its own sales team and a network of exclusive distributors on all continents. Their clients include academic laboratories, private laboratories, and researchers who are looking to implement innovative and robust microbiology contents. It is important for individuals to inquire about the registration status of ABL’s products to comply with local regulations. Only Research Use Only (RUO) tests are available for sale in the USA as listed on the FDA website. For more information, please visit www.abldiagnostics.com.
VELA Diagnostics is a leading provider of integrated IVD system solutions, from sample to result. Their test solutions use the automated Sentosa platform, providing the unique ability to leverage one system for NGS and PCR testing in infectious disease and oncology. VELA’s products are available in several markets, including the US, EU, PRC, and the UK. All Sentosa products listed above are by VELA Diagnostics.
For media inquiries, please contact:
ABL Diagnostics
Chalom Sayada
General Manager
Tel.: +33 7 83 64 68 50
info@abldiagnostics.com
VELA Diagnostics
Lucia Vira
lucia.vira@veladx.com
This press release contains implicitly or explicitly certain forward-looking statements concerning ABL Diagnostics and its business. Such forward-looking statements are based on assumptions that ABL Diagnostics considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, and they are subject to numerous risks, including the risks set forth in the “Risk Factors” section of the universal registration document filed with the AMF on July 12, 2022 under number 22-296, available on the website of ABL Diagnostics (www.abldiagnostics.com) and to the development of economic conditions, financial markets and the markets in which ABL Diagnostics operates. The forward-looking statements contained in this press release are also subject to risks not yet known to ABL Diagnostics or not currently considered material by ABL Diagnostics. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of ABL Diagnostics to be materially different from such forward-looking statements.
This press release and the information contained herein do not constitute and should not be construed as an offer or an invitation to sell or subscribe, or the solicitation of any order or invitation to purchase or subscribe for ABL Diagnostics shares in any country. The distribution of this press release in certain countries may be a breach of applicable laws. The persons in possession of this press release must inquire about any local restrictions and comply with these restrictions.
Derick is an experienced reporter having held multiple senior roles for large publishers across Europe. Specialist subjects include small business and financial emerging markets.